Literature DB >> 33536605

Bsep expression in hilar cholangiocarcinoma of rat model.

Meng-Yu Zhang1, Jie-Ping Wang2, Kai He3, Xian-Ming Xia3.   

Abstract

Develop a rat model of hilar cholangiocarcinoma for detecting bile salt export pump (Bsep) expression in hilar cholangiocarcinoma tissues, in order to provide a new therapeutic target for the gene therapy of hilar cholangiocarcinoma. Sixty male Wistar rats (body weight, 190 ± 8 g) were randomly divided into three groups (the experimental group, the control group and the sham operation group, n = 20 each) as follows: The three groups were fed a standard diet, the experimental group was injected by cholangiocarcinoma QBC939 cell suspension along the hilar bile duct into the bile duct bifurcation with microsyringe, the control group was injected by normal saline, the sham operation group did not inject anything. Every day assess the rats' mental state, diet, and motion by using Basso-Beattie-Bresnahan and combined behavioral score. At 4 weeks, one rat of the experimental group was sacrificed after it was administered anesthesia, and we recorded changes in hilar bile duct size, texture, and form. This procedure was repeated at 6 weeks. After 6 weeks, hilar cholangiocarcinoma developed only in the experimental group, thereby establishing an experimental model for studying QBC939-induced hilar cholangiocarcinoma. Tumor formation was confirmed by pathological examination, and hilar bile duct tissues were harvested from both the groups. A real-time polymerase chain reaction assay and an immunohistochemical assay were used to analyze the expression of Bsep in hilar bile duct tissues of each group. From the second week, the rats in experimental group began to eat less, and their body mass decreased compared with control group and sham operation group. After 6 weeks, we detected hilar cholangiocarcinoma in the hilar bile duct tissues of 18 rats (90%) in the experimental group. In the experimental group with hilar cholangiocarcinoma, we found that the levels of total cholesterol, total bilirubin, and direct bilirubin were higher compared with those in the control group and sham operation group. Simultaneously, muddy stones emerged from the bile ducts of rats in the experimental group. The Bsep/Gapdh mRNA ratio in hilar cholangiocarcinoma, control group and sham operation group differed markedly. Light microscopy revealed a granular pattern of Bsep protein expression which reacted with the anti-Bsep antibody. Each section was randomly divided into six regions, with 80 cells were observed in every region. Sections with > 10% positive cells were designated positive, Sections with < 10% positive cells were designated negative. Each group included 4800 cells. In the experimental group, 1200 cells (25%) were positive, in the control group, 3648 cells (76%) were positive and in the sham operation group 3598 cells (75%) were positive, and this difference was statistically significant. Bsep expression significantly decreased in hilar cholangiocarcinoma of rats than those in control group and sham operation group, suggesting that drugs targeting Bsep are a new strategy for hilar cholangiocarcinoma.

Entities:  

Year:  2021        PMID: 33536605     DOI: 10.1038/s41598-021-82636-z

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  3 in total

1.  Cholangitis mimicking hilar cholangiocarcinoma.

Authors:  A Barberis; U G Rossi; M Filauro
Journal:  Rev Gastroenterol Mex (Engl Ed)       Date:  2019-04-20

2.  [The safety and effect of transhepatic hilar approach for the treatment of bismuth type Ⅲ and Ⅳ hilar cholangiocarcinoma].

Authors:  M He; H L Wang; J Y Yan; S W Xu; W Chen; J Wang
Journal:  Zhonghua Wai Ke Za Zhi       Date:  2018-05-01

3.  Unilateral versus bilateral hilar stents for the treatment of cholangiocarcinoma: a multicenter international study.

Authors:  Judith Staub; Ali Siddiqui; Megan Murphy; Robert Lam; Meet Parikh; Douglas Pleskow; Georgios Papachristou; Reem Sharaiha; Usama Iqbal; David Loren; Thomas Kowalski; Arish Noor; Tayebah Mumtaz; Ichiro Yasuda; Samuel Thomas; Abdul Hsaeeb; Jennifer Herrick; Tom Greene; Douglas G Adler
Journal:  Ann Gastroenterol       Date:  2020-02-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.